Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis-Reference-Cited by-同舟云学术

Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis

Published:2018-11 Issue: Volume:125 Page:212-217
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Yamaguchi Teppei^ORCID,Shimizu Junichi,Hasegawa Takaaki,Horio Yoshitsugu,Inaba Yoshitaka,Yatabe Yasushi^ORCID,Hida Toyoaki

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference37 articles.

1. Does interstitial lung disease predispose to lung cancer?;Daniels;Curr. Opin. Pulm. Med.,2005

2. The epidemiology of interstitial lung disease and its association with lung cancer;Raghu;Br. J. Cancer,2004

3. Prevalence of lung cancer in patients with interstitial lung disease is higher than in those with chronic obstructive pulmonary disease;Jung;Medicine (Baltim.),2018

4. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study;Kudoh;Am. J. Respir. Crit. Care Med.,2008

5. Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs;Niho;Jpn. J. Clin. Oncol.,2006

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcome of immune checkpoint inhibitor treatment in non-small cell lung cancer patients with interstitial lung abnormalities: clinical utility of subcategorizing interstitial lung abnormalities;Cancer Immunology, Immunotherapy;2024-09-05

2. 18F-FDG-PET/CT Uptake by Noncancerous Lung as a Predictor of Interstitial Lung Disease Induced by Immune Checkpoint Inhibitors;Academic Radiology;2024-09

3. Lung Cancer and Interstitial Lung Diseases;Cancers;2024-08-13

4. Epithelial–mesenchymal transition in chemoradiation‐induced lung damage: Mechanisms and potential treatment approaches;Journal of Biochemical and Molecular Toxicology;2024-08

5. Risk factors for severe immune‐related pneumonitis after nivolumab plus ipilimumab therapy for non‐small cell lung cancer;Thoracic Cancer;2024-06-03